Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-08-05
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-02 (study day 90.0); relationship: PROBABLE
Data queries
No data queries.